Understand the source comparison
TB-4 vs BPC-157 vs GHK-Cu: Mechanism Comparison
TB-4 Actin sequestration; regulates cytoskeletal reorganisation during wound healing ~90 minutes systemic; 48–72 hours tissue effect Inflammatory + proliferative (days 0–21) 2–3× weekly subcutaneous Best for diffuse tissue repair, angiogenesis, reducing fibros
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- TB-4
- Actin sequestration; regulates cytoskeletal reorganisation during wound healing
- ~90 minutes systemic; 48–72 hours tissue effect
- Inflammatory + proliferative (days 0–21)
- 2–3× weekly subcutaneous
- Best for diffuse tissue repair, angiogenesis, reducing fibrosis. Does NOT work via growth factor pathways.
- BPC-157
- Growth factor upregulation (VEGF, FGF-2); promotes angiogenesis and fibroblast migration
- ~4 hours
- Acute injury + remodeling (days 0–28)
- Daily subcutaneous or oral
- Best for localised tendon/ligament injuries. Works via growth factor signaling, not cytoskeletal regulation.
- GHK-Cu
- Copper-binding tripeptide; modulates MMP activity and collagen synthesis
- ~60 minutes
- Remodeling phase (days 14–60)
- Daily subcutaneous or topical
- Best for scar reduction and collagen remodeling. Minimal acute-phase effect. Mechanism is extracellular matrix regulation.
- TB-4 and BPC-157 are often stacked in research protocols, but the mechanisms do not overlap. TB-4 regulates intracellular actin dynamics, while BPC-157 upregulates extracellular growth factors. GHK-Cu is typically reserved for later-stage remodeling to reduce keloid formation and improve collagen alignment.